Nanopharm CEO Jag Shur has announced the addition of three new members of the company’s management team in a LinkedIn post. The new hires include two OINDP experts: Dave Farrow, who joins the company as Director of Operations, and Chris Vernall as Director of Business Development.
Farrow was most recently Head of Development at Albany Molecular Research, Inc. and was previously Head of Inhalation at Charles River Laboratories. His career has also included stints at Vectura, Novartis, and Sanofi Aventis. Vernall is returning to Nanopharm after a number of years at Intertek Melbourn where he was most recently Business Development Director. His previous role at Nanopharm was as Inhalation Scientist.
Nanopharm, which was acquired by Aptar Pharma in June 2019, is expanding its team “to support our customer base and employees as we continue to grow the business,” Shur explains, adding, “We are now all set to deliver new solutions and technologies in the OINDP arena to provide value to our clients.” According to Shur, the company is anticipating the launch of services related to dissolution characterization for OINDPs and “formulation technology solutions for low carbon emission inhalers.”
